Results 91 to 100 of about 10,093 (182)

OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION

open access: yesПедиатрическая фармакология, 2007
Antibodies to IgE are a totally new class of medications currently used to enhance the supervision over severe persistent atopic bronchial asthma. Omalizumab is the most well studied, first and only medication of this group, which is recommended for the ...
T.V. Kulichenko
doaj   +2 more sources

Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry

open access: yesAllergy, Volume 81, Issue 8, Page 2804-2814, August 2026.
Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...
Pavel Kolkhir   +25 more
wiley   +1 more source

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

open access: yesAllergy, Volume 81, Issue 8, Page 2582-2632, August 2026.
ABSTRACT This update and revision of the international guideline for urticaria was developed in accordance with the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is an initiative of the Global Allergy and Asthma Excellence Network (GA2LEN) and its Urticaria and ...
Torsten Zuberbier   +221 more
wiley   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1406-1419, August 2026.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla   +33 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

The role of omalizumab in the treatment of adults with severe allergic asthma

open access: yesZdravniški Vestnik, 2013
Backg round: Omalizumab is a recombinant humanized anti-IgE antibody. It has been used in the treatment of severe allergic asthma since 2007 in Slovenija.
Sabina Škrgat Kristan
doaj  

Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria. [PDF]

open access: yesJ Inflamm Res
Ensina LF   +5 more
europepmc   +1 more source

Algorithms in Allergy: Hereditary Angioedema

open access: yes
Allergy, Volume 81, Issue 8, Page 3008-3012, August 2026.
Konrad Bork   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy